Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Regulatory News (SYNC)

Share Price Information for Syncona (SYNC)

Share Price is delayed by 15 minutes
Get Live Data
99.90    2.90 (2.99%)
Bid:
99.10
Ask:
100.40
Spread: 1.30 (1.312%)
Market Cap: £607.58m
SYNC Live PriceLast checked at - London Stock Exchange

Intraday Syncona Share Chart

Directorate Change

31 Dec 2021 07:00

RNS Number : 6395W
Syncona Limited
31 December 2021
 

Syncona Limited

 

Directorate Change

 

31 December 2021

 

Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life science, notes that as previously announced, Nigel Keen and Nicholas Moss step down as Non-Executive Directors on 31 December 2021.

 

Virginia Holmes will become Senior Independent Director and Gian Piero Reverberi will become Chair of the Remuneration Committee, in each case from 1 January 2022.

 

[ENDS]

 

Enquiries

 

Syncona Ltd

Natalie Garland-Collins / Fergus Witt

Tel: +44 (0) 7714 916615

 

FTI Consulting

Ben Atwell / Tim Stamper

Tel: +44 (0) 20 3727 1000

 

Company Secretary

Citco Fund Services (Guernsey) Limited

Company Secretary

Tel: +44 (0) 1481 758228

 

About Syncona:

Syncona's purpose is to invest to extend and enhance human life. We do this by founding and building companies to deliver transformational treatments to patients in areas of high unmet need.

 

Our strategy is to found, build and fund companies around exceptional science to create a diversified portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFELFSDEFSEEE
Date   Source Headline
30th Jul 201812:45 pmPRNDirectors Dealings
25th Jul 20187:00 amPRNIssue of shares pursuant to the 2018 dividend
29th Jun 201812:45 pmPRN2018 Dividend Scrip Reference Price
29th Jun 201810:15 amPRNMonthly Factsheet - May 2018
29th Jun 201810:10 amPRNNet Asset Value(s)
27th Jun 20187:00 amPRNPublication of 2018 Annual Report and Notice of AGM
26th Jun 20185:30 pmPRNAutolus closes IPO
22nd Jun 20187:00 amPRNAutolus update on IPO
19th Jun 20187:00 amPRNSyncona makes £85 million commitment to Freeline
14th Jun 201811:06 amPRNNightstar receives RMAT designation in Choroideremia
14th Jun 20187:00 amPRNSyncona Limited Full Year Results 2018
8th Jun 201811:35 amPRNUpdate on Autolus proposed IPO in the United States
6th Jun 201811:40 amPRNNightstar reports Q1 Financial Results
31st May 20182:19 pmPRNNet Asset Value(s)
31st May 20182:19 pmPRNMonthly Factsheet - April 2018
8th May 20187:00 amPRNAutolus files for proposed IPO in the US
2nd May 20187:00 amPRNBlue Earth portfolio expansion, strong performance
27th Apr 20181:44 pmPRNMonthly Factsheet - March 2018
27th Apr 20181:44 pmPRNNet Asset Value(s)
4th Apr 20187:00 amPRNNightstar Reports 2017 Financial Results
29th Mar 201811:31 amPRNMonthly Factsheet - February 2018
29th Mar 201811:25 amPRNNet Asset Value(s)
9th Mar 20187:00 amPRNIntegration of the management of fund investments
6th Mar 20187:00 amPRNAutolus announces confidential filing for potential IPO
5th Mar 201811:33 amPRNNightstar initiates Pivotal Trial in Choroideremia
5th Mar 20187:00 amPRNDirectorate Change
27th Feb 20182:54 pmPRNMonthly Factsheet - January 2018
27th Feb 20182:51 pmPRNNet Asset Value(s)
30th Jan 20183:37 pmPRNMonthly Factsheet - December 2017
30th Jan 20183:35 pmPRNNet Asset Value(s)
18th Jan 20184:56 pmPRNDirectors Dealings
2nd Jan 20189:47 amPRNRelease of Key Information Document
22nd Dec 20171:18 pmPRNNet Asset Value(s)
22nd Dec 20171:18 pmPRNMonthly Factsheet - November 2017
12th Dec 20173:24 pmPRNChange in Investment Manager
29th Nov 20172:28 pmPRNMonthly Factsheet - October 2017
29th Nov 20172:19 pmPRNNet Asset Value(s)
22nd Nov 20177:00 amPRNInterim Results
27th Oct 20173:38 pmPRNNet Asset Value(s)
27th Oct 20173:37 pmPRNMonthly Factsheet - September 2017
16th Oct 201710:39 amPRNDirectorate Change
12th Oct 20179:58 amPRNDirectors Dealings
3rd Oct 20177:00 amPRNNightstar announces closing of IPO
29th Sep 20171:51 pmPRNMonthly Factsheet - August 2017
29th Sep 20171:47 pmPRNNet Asset Value(s)
28th Sep 20177:00 amPRNNightstar lists on NASDAQ
26th Sep 20177:00 amPRNSyncona leads US$80m Autolus Series C investment round
18th Sep 20177:00 amPRNAutolus commences clinical trial programmes
15th Sep 20171:02 pmPRNUpdate on Nightstar proposed NASDAQ IPO
8th Sep 20174:39 pmPRNDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.